Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novocure Limited (NASDAQ: NVCR) SEC filings page on Stock Titan provides access to the company’s official disclosures as a registrant under U.S. securities laws. Novocure is incorporated in Jersey and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37565. These filings document material events, financial performance and regulatory updates related to its Tumor Treating Fields (TTFields) oncology business.
Among the key documents available are Form 8-K current reports, which Novocure uses to announce items such as quarterly financial results, clinical trial decisions and regulatory milestones. Recent 8-K filings reference press releases on net revenues, active patient counts on TTFields therapy, and the termination of the LUNAR-4 trial, as well as regulatory approvals like Japan’s Ministry of Health, Labour and Welfare decision on Optune Lua for certain NSCLC patients.
Investors and researchers can also use this page to monitor periodic reports such as annual and quarterly filings when available, which typically include consolidated financial statements, details on research, development and clinical study expenses, and discussions of sales, marketing and general and administrative costs. These documents provide structured insight into Novocure’s TTFields-based product portfolio, including Optune Gio and Optune Lua, and the company’s spending on clinical and regulatory programs in glioblastoma, non-small cell lung cancer, mesothelioma and pancreatic cancer.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand changes in revenue, operating expenses, cash position and key clinical or regulatory disclosures. Users can also review insider and management-related filings such as Forms 3, 4 and 5 when available, to track equity transactions by directors and officers.
With real-time updates from EDGAR and AI-assisted explanations, this page serves as a focused resource for analyzing Novocure’s regulatory record, financial condition and material events that shape its TTFields oncology platform.
The Vanguard Group filed an amendment to a Schedule 13G/A reporting beneficial ownership of 0 shares of Novocure Ltd Common Stock, representing 0% of the class.
The filing states that on January 12, 2026 Vanguard completed an internal realignment and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim and dated 03/26/2026.
Novocure reported positive topline Phase 2 PANOVA-4 results for Tumor Treating Fields (TTFields) used with atezolizumab, gemcitabine and nab-paclitaxel as first-line therapy for metastatic pancreatic ductal adenocarcinoma.
The regimen achieved a disease control rate of 74.4% in 78 patients, compared with 48% in 431 patients receiving gemcitabine and nab-paclitaxel alone in a historical Phase 3 control, a 26.4% difference with strong statistical significance (1-sided p < 0.001). Objective response rate was 34.6% and median overall survival was 9.7 months. Treatment duration and safety for TTFields were consistent with prior studies, and the company plans to present additional data at a future scientific forum.
NovoCure Ltd former Chief Medical Officer Nicolas Leupin reported an open-market sale of 1,100 Ordinary Shares on March 4, 2026 at a weighted average price of $13.3054 per share. According to the disclosure, this sale was required to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. Following this transaction, Leupin directly held 102,979 Ordinary Shares.
NovoCure Ltd reported that former Chief Executive Officer Ashley Cordova had 17,638 ordinary shares withheld on March 4, 2026 to cover tax obligations tied to vesting Restricted Stock Units. The shares were withheld by the issuer at $13.30 per share in a non-discretionary, tax-withholding disposition. After this transaction, Cordova directly owned 422,570 ordinary shares.
NovoCure Ltd reported that its General Counsel, Ben Arye Barak, received new equity awards. He was granted stock options for 73,340 ordinary shares at an exercise price of $0.00 per share, bringing his total options reported in this line to 73,340.
He also acquired 50,125 ordinary shares in the form of restricted share units at $0.00 per share, increasing his directly held ordinary shares to 242,453. The restricted share units are scheduled to vest in three equal annual installments on the first, second and third anniversaries of the grant date, subject to his continued employment. The options are scheduled to vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date, also subject to continued employment.
NovoCure Ltd chief medical and innovation officer Uri Weinberg reported several equity transactions. He sold 6,412 ordinary shares at a weighted average price of $13.3054 per share to cover tax withholding tied to restricted stock unit vesting, a sale mandated by the company’s equity plan. Following this sale, he held 267,190 ordinary shares. Weinberg also received 50,125 ordinary shares as a grant of restricted share units and 73,340 stock options, both at a grant price of $0.00. The restricted share units are scheduled to vest in three equal parts on the first, second, and third anniversaries of the grant date, while the stock options vest in four equal parts on the first through fourth anniversaries, each subject to his continued employment.
NovoCure Ltd Chief Financial Officer Christoph Brackmann reported a mix of equity grants and a small mandated share sale. He received 55,137 ordinary shares as a restricted stock award, which are scheduled to vest in equal parts on the first, second and third anniversaries of the grant date, subject to continued employment.
He was also granted options over 80,674 ordinary shares, vesting in equal parts on the first through fourth anniversaries, subject to continued employment. In connection with restricted stock unit vesting, he sold 6,412 ordinary shares at a weighted average price of $13.3054 per share to cover tax withholding obligations under a mandatory “sell to cover” arrangement, leaving 182,842 ordinary shares held directly afterward.
NovoCure Ltd Chief Executive Officer Leonard Frank X reported a mix of equity awards and a small share sale. He received a grant of 150,000 ordinary shares in the form of restricted share units that vest in three equal parts on the first, second and third anniversaries of the grant date, subject to continued employment. He also received stock options for 216,388 ordinary shares that vest in four equal parts on the first through fourth anniversaries of the grant date, also subject to continued employment. To cover tax withholding obligations from restricted stock unit vesting, he sold 5,607 ordinary shares in a mandated “sell to cover” transaction at a weighted average price of $13.3054 per share, executed in multiple trades between $13.21 and $13.445. Following these transactions, he directly holds 493,793 ordinary shares and 216,388 stock options.
NovoCure Ltd Chief Operating Officer Paravasthu Mukund reported a combination of equity grants and share sales. On March 3, 2026, he received 45,112 Ordinary Shares as a grant, described as restricted share units that vest in equal parts on the first, second and third anniversaries of the grant date, subject to continued employment. On the same date, he was granted stock options over 7,518 Ordinary Shares and 58,488 Ordinary Shares, with these options scheduled to vest in equal parts on the first, second, third and fourth anniversaries of the grant date, also conditioned on continued employment.
Subsequently, Mukund executed open-market sales of 5,377 Ordinary Shares on March 4, 2026 at a weighted average price of $13.3054 per share and 43,246 Ordinary Shares on March 5, 2026 at a weighted average price of $13.7740 per share. A footnote states that the number of shares sold was required to cover tax withholding obligations related to the vesting of restricted stock units and was mandated by NovoCure's award agreement as a "sell to cover" transaction, rather than a discretionary trade. After the March 5 sale, Mukund directly held 72,832 Ordinary Shares.
NovoCure Ltd's Chief Human Resources Officer, Michal Nath Puri, reported equity compensation and a related tax sale. On March 3, 2026, he received 40,100 ordinary shares as restricted share units that vest over three years and 58,672 stock options vesting over four years. On March 4, 2026, he sold 1,100 ordinary shares at a weighted average price of $13.3054 in a mandated “sell to cover” transaction to satisfy tax withholding, and held 201,322 ordinary shares directly afterward.